Drug Trial Radar · NCT05288543
A Study of Orally Administered IPG7236 in Healthy Adult Participants
Last checked: Nov 19, 2026Latest source record: Dec 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
63
Actual
Start
Apr 7, 2022
Primary completion
Mar 31, 2023
Study completion Nov 26, 2025
Sponsor
- Lead sponsor
- Nanjing Immunophage Biotech Co., LtdIndustry
- Sponsor type
- Industry
- Collaborators
- Novotech (Australia) Pty Limited
- First posted
- Mar 21, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The study is a phase 1, randomized, double-blind, placebo-controlled, single and multiple dose escalation study to evaluate the safety, tolerability, pharmacokinetic and food effect of orally administered IPG7236 in healthy adult participants.
Conditions
- Atopic Dermatitis
Interventions
IPG7236- Single ascending doseDrug
Subjects will receive IPG7236 tablets orally once on Day 1 in a fasted state
IPG7236- Multiple ascending doseDrug
Subjects will receive IPG7236 tablets orally once daily for 10 days from Day1 to Day 10 in a fasted state
Placebo (Part A)Other
Subjects will receive IPG7236 tablets orally once on Day 1 (Part A) or once daily for 10 days from Day1 to Day 10 (Part B) in a fasted state
Primary outcomes
What the sponsor says the trial is designed to measure.
- To assess the safety and tolerability of IPG7236 after ascending single oral doses through adverse events as assessed by National Cancer Institute-Common Terminology Criteria for Adverse Events v5Time frame: Up to 36 days
- To assess the safety and tolerability of IPG7236 after ascending multiple oral doses through adverse events as assessed by National Cancer Institute-Common Terminology Criteria for Adverse Events v5Time frame: Up to 45 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Scientia Clinical Research Ltd
Randwick, New South Wales, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.